REAL-LIFE EXPERIENCE WITH POMALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Cubillas, Garcia de la Torre Damian [1 ]
Inigo, Rodriguez Belen [1 ]
Alfayate, Lobo Ana [1 ]
Menendez, Cuevas Marina [1 ]
Bolanos, Calderon Estefania [1 ]
Medina, Salazar Sissy Fiorella [1 ]
Mateo, Morales Marta [1 ]
Pena, Cortijo Ascension [1 ]
Perez, Lopez Cristina [1 ]
Polo, Zarzuela Marta [1 ]
Calo, Perez Aida [1 ]
Colas, Lahuerta Blanca [1 ]
Gomez, Alvarez Miguel [1 ]
Escribano, Serrat Silvia [1 ]
Estival, Monteliu Pablo [1 ]
Gulino, Horacio [1 ]
Daorta, Melisa [1 ]
Moreno, Paredes Nahir Daniela [1 ]
Benavente, Cuesta Celina [1 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-027
引用
下载
收藏
页码：151 / 151
页数：1
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE
    Soyer, N.
    Patir, P.
    Uysal, A.
    Duran, M.
    Unal, H. D.
    Tombuloglu, M.
    Sahin, F.
    Vural, F.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S36 - S36
  • [42] Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience
    Claudio Cerchione
    Lucio Catalano
    Anna Emanuele Pareto
    Marco Picardi
    Fabrizio Pane
    Supportive Care in Cancer, 2015, 23 : 301 - 302
  • [43] ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Rocco, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : S82 - S82
  • [44] Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
    Borg, Sixten
    Nahi, Hareth
    Hansson, Markus
    Lee, Dawn
    Elvidge, Jamie
    Persson, Ulf
    ACTA ONCOLOGICA, 2016, 55 (05) : 554 - 560
  • [45] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2019, 134
  • [46] EXPERIENCE WITH THE USE OF POMALIDOMIDE-DEXAMETASONE IN THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Galan Vega, J.
    Alvarez Juarez, M. A.
    Herrera, F.
    Lopez Prieto, C.
    Car-Mona Zabala, I
    Escolano Escobar, C.
    Somolinos De Marcos, N.
    Ona Compan, F.
    Benito Parra, L.
    HAEMATOLOGICA, 2019, 104 : 406 - 406
  • [47] Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation
    Zambello, Renato
    Bonaldi, Laura
    Berno, Tamara
    Martines, Annalisa
    Sechettin, Erica
    De March, Elena
    Branca, Antonio
    Lico, Albana
    Minotto, Claudia
    Briani, Chiara
    Gurrieri, Carmela
    Temporin, Francesca
    Battistutta, Claudia
    Piazza, Francesco
    Cavraro, Monica
    Trentin, Livio
    Semenzato, Gianpietro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (10): : 592 - 598
  • [48] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
  • [49] Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status
    Decaux, Olivier
    Lafore, Radhia
    Iaquinta, Daniel
    Tekle, Christina
    Leleu, Xavier
    BLOOD, 2022, 140 : 10969 - 10970
  • [50] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    BLOOD CANCER JOURNAL, 2018, 8
12345